• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

BioMarin Pharmaceutical

edit

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Recent Milestones

edit

• 
  BioMarin Pharmaceutical acquired Zacharon Pharmaceuticals. (1/7/13)
  Posted 1/9/13 at 12:57am via yahoo.com
• 
  BioMarin Pharmaceutical acquired Zystor for $115M. (8/18/10)
  Posted 8/18/10 at 10:09am via fiercebiotech.com
• 
  BioMarin Pharmaceutical acquired Huxley Pharmaceuticals for $58.5M. (10/26/09)
  Posted 1/25/10 at 11:09pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. BioMarin Acquires Zacharon Pharmaceuticals (finance.yahoo.com) [edit]
2. BioMarin snares orphan drug upstart in $115M buyout (fiercebiotech.com) [edit]
3. BioMarin Acquires Huxley Pharmaceuticals, Inc. (fiercebiotech.com) [edit]